IP Library Granted Patent US 10,111,944
Granted Patent B2
US 10,111,944 · App. 15/324,964 · Granted Oct 30, 2018

Influenza virus vaccines and uses thereof

Inventors: Antonietta Impagliazzo (Leiden, NL); Jan Willem Meijberg (Leiden, NL); Katarina Radosevic (Nootdorp, NL); Michelle Wagner (San Diego, CA); Zhaoqing Ding (San Diego, CA)
Assignee: Janssen Vaccines & Prevention B.V.
A61K39/145A61K39/12C07K14/005C07K14/11C07K16/1018C12N7/00A61K2039/505A61K2039/53A61K2039/55577C07K2317/55C07K2317/70C07K2317/732C07K2317/76C07K2317/92C12N2760/16122C12N2760/16134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,111,944
App. No.
15/324,964
Granted
Oct 30, 2018
Kind
B2
Abstract

Provided herein are influenza hemagglutinin stem domain polypeptides, methods for providing hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use, in particular in the detection, prevention and/or treatment of influenza.

Claims (15)

1. An influenza hemagglutinin stem domain polypeptide comprising the amino acid sequence:

DTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENGGGGKYVCSAKLRMVTGLRNX 1 PS X 2 QSQGLFGAIAGX 3 X 4 EGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQNAINGITNK VNSVIEKX 5 NTQX 6 TAX 7 GKEX 8 NKX 9 ERRMKQIEDKIEEIESKIWCYNAELLVLLENERTL DFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKIDG (SEQ ID NO: 146),

wherein X 1 is K, X 2 is K, X 3 is F, X 4 is T, X 5 is M, X 6 is Y, X 7 is I, X 8 is Y, and X 9 is S.

2. The influenza hemagglutinin stem domain polypeptide according to claim 1 , wherein the polypeptide selectively binds to the antibodies CR6261 and/or CR9114.

3. A nucleic acid molecule encoding the polypeptide of claim 1 .

4. A vector comprising the nucleic acid molecule of claim 3 .

5. A composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

6. A composition comprising the nucleic acid molecule according to claim 3 and a pharmaceutically acceptable carrier.

7. A method of inducing an immune response against an influenza virus in a subject in need thereof, the method comprising administering to the subject in need thereof the polypeptide according to claim 1 .

8. A method of inducing an immune response against an influenza virus in a subject in need thereof, the method comprising administering to the subject in need thereof the nucleic acid molecule according to claim 3 .

9. A method of inducing an immune response against an influenza virus in a subject in need thereof, the method comprising administering to the subject in need thereof the vector according to claim 4 .

10. A composition comprising the vector according to claim 4 and a pharmaceutically acceptable carrier.

11. The influenza hemagglutinin stem domain polypeptide according to claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:81.

12. The influenza hemagglutinin stem domain polypeptide according to claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:91.

13. The influenza hemagglutinin stem domain polypeptide according to claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:101.

Assignments (2)
CHANGE OF NAME Recorded Feb 1, 2017
From: CRUCELL HOLLAND B.V.
To: JANSSEN VACCINES & PREVENTION B.V.
Reel/Frame 041588/0310 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2017
From: IMPAGLIAZZO, ANTONIETTA; MEIJBERG, JAN WILLEM; RADOSEVIC, KATARINA; WAGNER, MICHELLE; DING, ZHAOQING
To: CRUCELL HOLLAND B.V.
Reel/Frame 041002/0521 →
Priority Claims (2)
EP 14176451 · Jul 10, 2014 · regional
EP 14195133 · Nov 27, 2014 · regional
Continuity (2)
Provisional Application 62062746 · Oct 10, 2014
Related Publication 20170209564A1 · Jul 27, 2017